Join
Live feed
·
INSIDERFilingvia Quantisnow
Oruka Therapeutics Inc. logo

Director Dambkowski Carl sold $2,454,382 worth of shares (35,000 units at $70.13) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 38,743 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ORKA· Oruka Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ORKA (Oruka Therapeutics Inc.) and more on Quantisnow.